Literature DB >> 6219888

Right heart impairment in sarcoidosis: haemodynamic and echocardiographic study.

G Rizzato, A Pezzano, G Sala, R Merlini, L Ladelli, G Tansini, G Montanari, L Bertoli.   

Abstract

62 patients with histologically confirmed sarcoidosis (7 with Stage 0, 9 with Stage I, 20 with Stage II, 26 with Stage III) underwent right heart haemodynamics (Swan Ganz) and M-mode echocardiography. Haemodynamic study showed mild to moderate pulmonary hypertension in many patients with Stage II and III sarcoidosis, and 5 patients with Stage 0 healed sarcoidosis, showed borderline values of right sided pressures. Echocardiographic study showed increased right ventricular index (RVI) and right ventricular anterior wall thickness (RVAWT) in most patients. The good correlations between echocardiographic and haemodynamic data suggest that echocardiography may be a useful technique for the non-invasive assessment of the effects of pulmonary hypertension on the right heart in sarcoidosis.

Entities:  

Mesh:

Year:  1983        PMID: 6219888

Source DB:  PubMed          Journal:  Eur J Respir Dis        ISSN: 0106-4339


  9 in total

Review 1.  A concise review of pulmonary sarcoidosis.

Authors:  Robert P Baughman; Daniel A Culver; Marc A Judson
Journal:  Am J Respir Crit Care Med       Date:  2010-10-29       Impact factor: 21.405

2.  Pulmonary hypertension associated with sarcoidosis: mechanisms, haemodynamics and prognosis.

Authors:  H Nunes; M Humbert; F Capron; M Brauner; O Sitbon; J-P Battesti; G Simonneau; D Valeyre
Journal:  Thorax       Date:  2005-10-14       Impact factor: 9.139

Review 3.  Cardiac sarcoidosis: diagnostic, prognostic, and therapeutic considerations.

Authors:  M Sekiguchi; Y Yazaki; M Isobe; M Hiroe
Journal:  Cardiovasc Drugs Ther       Date:  1996-11       Impact factor: 3.727

Review 4.  Pulmonary hypertension caused by sarcoidosis.

Authors:  Enrique Diaz-Guzman; Carol Farver; Joseph Parambil; Daniel A Culver
Journal:  Clin Chest Med       Date:  2008-09       Impact factor: 2.878

Review 5.  Epidemiology, Pathogenesis, and Clinical Approach in Group 5 Pulmonary Hypertension.

Authors:  Mazen Al-Qadi; Barbara LeVarge; H James Ford
Journal:  Front Med (Lausanne)       Date:  2021-03-25

6.  Pulmonary hypertension in parenchymal lung disease.

Authors:  Iraklis Tsangaris; Georgios Tsaknis; Anastasia Anthi; Stylianos E Orfanos
Journal:  Pulm Med       Date:  2012-10-10

7.  Right Ventricular Abnormalities on Cardiovascular Magnetic Resonance Imaging in Patients With Sarcoidosis.

Authors:  Pratik S Velangi; Ko-Hsuan Amy Chen; Felipe Kazmirczak; Osama Okasha; Lisa von Wald; Henri Roukoz; Afshin Farzaneh-Far; Jeremy Markowitz; Prabhjot S Nijjar; Maneesh Bhargava; David Perlman; Mehmet Akçakaya; Chetan Shenoy
Journal:  JACC Cardiovasc Imaging       Date:  2020-01-15

Review 8.  Pulmonary hypertension associated with sarcoidosis.

Authors:  Robert P Baughman
Journal:  Arthritis Res Ther       Date:  2007       Impact factor: 5.156

9.  Can a New Scoring System Improve Prediction of Pulmonary Hypertension in Newly Recognised Interstitial Lung Diseases?

Authors:  Małgorzata Sobiecka; Katarzyna Lewandowska; Jarosław Kober; Monika Franczuk; Agnieszka Skoczylas; Witold Tomkowski; Jan Kuś; Monika Szturmowicz
Journal:  Lung       Date:  2020-03-23       Impact factor: 2.584

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.